Biogen (BIIB) Protective Put Calculator
Calculator · free · no signup · BIIBPrice a protective put, zero-cost collar, or put spread on Biogen. Annual cost, max loss, upside cap, tax treatment, auto-filled from current BIIB option chain.
AlphaLatitude Inc. · Free ToolsOur tools respect your browsing privacy. Independently verified:
You priced one hedge. The beta picks the right hedge structure given your full equity stack and tax situation.
Request beta access →Related calculators: Stock Concentration Calculator
About Biogen
Biogen (BIIB) is a public Pharma/Biotech company, incorporated in Delaware and headquartered in Cambridge, MA.
Last close: $225.88 per share (as of 2026-10-01).
Equity grants at Biogen typically include restricted stock units (RSUs).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
Source: Wikipedia (CC BY-SA 4.0)
Walter Gilbert and Phillip Sharp, both later Nobel Prize winners, co-founded Biogen in 1978 with Kenneth Murray, Heinz Schaller, and Charles Weissmann, one of the first companies built around recombinant DNA research. Headquartered in Cambridge, Massachusetts, Biogen develops treatments for neurological and neuromuscular diseases, including multiple sclerosis drugs and Leqembi, an Alzheimer's therapy sold with partner Eisai. In March 2026 Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion in cash, a deal that closed in May 2026 and added two FDA-approved drugs, Empaveli and Syfovre, which generated a combined $689 million in 2025 revenue.
Sources: biogen.com · statnews.com · cnbc.com
Equity comp at Biogen
- RSUs use single-trigger vesting: shares become yours as each portion vests on schedule, and the value is taxed as ordinary income at that point. No IPO or acquisition is required.
Researched 2026-08-17.
OptionsAhoy is an independent tool and is not affiliated with, endorsed by, or sponsored by Biogen.
A protective put caps your downside on the BIIB position at a chosen floor; a zero-cost collar pays for that floor by capping the upside. This calculator prices both structures off the current BIIB option chain, with annual cost, max loss, and tax-treatment notes.
Example: a 5,000-share BIIB position at $225.88 is worth $1,129,400. A 1-year 30%-OTM put on that position typically runs 2-4% of position value per year (about $22,588 to $45,176) before any premium offset from a short call. The calculator prices both structures off BIIB's current option chain so you see the actual cost for your chosen floor, tenor, and cap.
All Biogen tools → · Use the generic Protect Your Stock Calculator for any company.
Biogen equity questions
- How much does it cost to hedge BIIB stock?
- The cost of a protective put depends on how far below the current price you set the floor, how long the protection lasts, and BIIB's option-implied volatility. A zero-cost collar lowers that cost by selling away some upside. The calculator above prices both structures off the current BIIB option chain and shows the annual cost, maximum loss, and tax treatment.
- Does Biogen grant ISOs, NSOs, or RSUs?
- Equity compensation at Biogen typically takes the form of restricted stock units (RSUs). Restricted stock units are taxed as ordinary income when they vest.
- Do Biogen RSUs use double-trigger vesting?
- No. Biogen restricted stock units (RSUs) use single-trigger vesting: each tranche becomes yours as it vests on schedule, taxed as ordinary income at that point, with no liquidity event required.
Find another companyPharma/Biotech peers
One piece of the puzzle.
OptionsAhoy plans your Biogen equity alongside hedging, vesting, and de-concentration, across bullish, neutral, and bearish market scenarios. Free during beta.